This bill requires the Federal Trade Commission to produce a comprehensive report within one year of enactment, and every year thereafter, examining foreign investment in the U.S. pharmaceutical industry. The report must assess how foreign ownership and manufacturing concentration affect America's ability to produce medicines and drug ingredients domestically, as well as examine the impact of foreign investment in DNA sequencing and storage technologies. The legislation also directs the FTC to analyze what happens when American pharmaceutical manufacturers move production overseas. The FTC will have the authority to conduct necessary studies and must publish an unclassified summary of its findings on a public website, with copies sent to Congress, the Commerce and Health and Human Services departments, and other relevant agencies. This bill essentially aims to increase transparency and monitoring of foreign involvement in the U.S. drug supply chain, with no specific funding amount mentioned in the legislation.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.